Practical aspects of prescribing antiparkinsonian drugs. The place of amantadines in the management of Parkinson’s disease

Treatment of Parkinson’s disease (PD) includes the administration of dopaminergic and occasionally non-dopaminergic drugs, in mono- or in combination therapy. One of the key drug used to treat Parkinson’s disease is levodopa considered a gold standard. In addition levodopa can also be used as a challenge test to confirm the accuracy of diagnosis of PD known as the “Levodopa challenge test”. However many non levodopa class of drugs are also used and consist of dopamine agonists (ADRs), MAO-B and COMT inhibitors, as well as drugs working on glutamate such as a group of drug with NMDA receptor inhibitor activity (amantadines). The successful treatment of PD therefore depends on the correct choice of drugs to initiate treatment and sustainance of such therapy. The main parameters for personolised treatment include the patient’s age, severity and pattern of motor deficit, the state of cognitive function and lifestyle. Levodopa, although the most effective, is almost invariably associated with motor fluctuations and dyskinesias. Before prescribing levodopa, in addition to MAO-B inhibitors and ADRs, amantadines can be used as a monotherapy. Once replacement of therapy is required, then it is necessary to use a coefficient to calculate an equivalent dose of levodopa known as the levodopa equivalent dose. Progression of PD is inevitable inspite of adequate symptomatic therapy and at the advanced stage of PD approaches for the management of motor complications of levodopa need to be considered. For motor fluctuations these strategies require a change in the dosage regimen of levodopa (daily dose and frequency of intake), as well as the addition of an adjunct drug – ADRs, MAO-B inhibitor or COMT inhibitor. When dyskinesias arise, the management depends on correct identification of the type of dyskiensias. The commonest type of dyskinesia is peak dose dyskinesias related to peak plasma levodopa levels after intake. Amantadine provides a quick and long-lasting antidyskinetic effect which has been confirmed in open label as well as double-blind placebo-controlled studies. Compared to аmantadine chloride, amantadine sulfate has more stable pharmacokinetic parameters and a better safety profile. In addition, parenteral administration of amantadine sulfate can be utilized for severely ill patients with akinetic crisis in PD. Amantadine also has a broad spectrum effect and these may include improvement of fatigue and apathy. Some data also suggest that the use of amantadine in patients may increase life expectancy, improve survival and reduce the risk of dementia.

Parkinson’s disease, levodopa, dopamine receptor agonists, MAO-B inhibitors, amantadines, amantadine sulfate, motor fluctuations, dyskinesias

1. Dorsey E.R., Elbaz A., Nichols E., Abd-Allah F., Abdelalim A., Adsuar J.C. et al. Global, Regional, and National Burden of Parkinson’s Disease, 1990–2016: a Systematic Analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939–953. doi: 10.1016/S14744422(18)30295-3.

2. Gibb W.R., Lees A.J. The Relevance of the Lewy Body to the Pathogenesis of Idiopathic Parkinson’s Disease. J Neurol Neurosurg Psychiatry. 1988;51(6):745–752. doi: 10.1136/jnnp.51.6.745.

3. Postuma R.B., Berg D., Stern M., Poewe W., Olanow C.W., Oertel W. et al. MDS Clinical Diagnostic Criteria for Parkinson’s Disease. Mov Disorders. 2015;30(12):1591–1601. doi: 10.1002/mds.26424.

4. Grosset D., Taurah L., Burn D.J., MacMahon D., Forbes A., Turner K. et al. A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson’s disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry. 2007;78(5):465–469. doi: 10.1136/jnnp.2006.098327.

5. Grosset D. Clinical diagnosis of parkinsonism and tremor. In: Okun M., Grosset K., Fernandez H., Grosset D. (eds.) Parkinson’s Disease: Clinican’s Desk Reference. Boca Raton, Florida: CRC Press; 2009. p. 176.

6. Clarke C.E., Davies P. Systematic Review of Acute Levodopa and Apomorphine Challenge Tests in the Diagnosis of Idiopathic Parkinson’s Disease. J Neurol Neurosurg Psychiatry. 2000;69(5):590–594. doi: 10.1136/jnnp.69.5.590.

7. Fox S.H., Katzenschlager R., Lim S.Y., Barton B., de Bie R.M.A., Seppi K. et al. International Parkinson and movement disorder society evidencebased medicine review: Update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2018;33(8):1248–1266. doi: 10.1002/mds.27372.

8. Ferreira J.J., Katzenschlager R., Bloem B.R., Bonuccelli U., Burn D., Deuschl G. et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol. 2013;20(1):5–15. doi: 10.1111/j.1468-1331.2012.03866.x.

9. Parkinson Study Group. A Controlled Trial of Rasagiline in Early Parkinson Disease: The TEMPO Study. Arch Neurol. 2002;59(12):1937–1943. doi: 10.1001/archneur.59.12.1937.

10. Olanow C.W., Rascol O., Hauser R., Feigin P.D., Jankovic J., Lang A. et al. A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson’s Disease. N Engд J Med. 2009;361(13):1268–1278. doi: 10.1056/NEJMoa0809335.

11. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., Lang A.E. A Five-Year Study of the Incidence of Dyskinesia in Patients With Early Parkinson’s Disease Who Were Treated With Ropinirole or Levodopa. New Engд J Med. 2000;342(20):1484–1491. doi: 10.1056/NEJM200005183422004.

12. Holloway R.G., Shoulson I., Fahn S., Kieburtz K., Lang A., Marek K. et al. Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A 4-year Randomized Controlled Trial. Arch Neurol. 2004;61(7):1044–1053. doi: 10.1001/archneur.61.7.1044.

13. Holloway R., Marek K., Biglan K., Dick A., Fahn S., Julian-Baros E. et al. Long-term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease. Arch Neurol. 2009;66(5):563–570. doi: 10.1001/archneur.66.1.nct90001.

14. Garcia-Ruiz P.J., Martinez Castrillo J.C., Alonso-Canovas A., Herranz Barcenas A., Vela L., Sanchez Alonso P. et al. Impulse control disorder in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85(8):840-844. doi: 10.1136/jnnp-2013-306787.

15. Shipilova N.N., Titova N.V., Kokaeva Z.G., Fedosova A.S., Klimov E.A., Katunina E.A. A clinical and genetic study of impulsive-compulsive disorders in patients with Parkinson’s disease. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(10):4–9. (In Russ.) doi: 10.17116/jnevro20181181014.

16. Rabinak C.A., Nirenberg M.J. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67(1):58–63. doi: 10.1001/archneurol.2009.294.

17. Danielczyk W. Twenty-five years of amantadine therapy in Parkinson’s disease. J Neural Transm Suppl. 1995;46:399–405. Available at: https://ncbi.nlm.nih.gov/pubmed/8821075.

18. Stoof J.C., Booij J., Drukarch B. Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications? Clin Neurol Neurosurg. 1992;94:4–6. doi: 10.1016/0303-8467(92)90006-o.

19. Butzer J.F., Silver D.E., Sahs A.L. Amantadine in Parkinson’s disease. A double-blind, placebo-controlled, crossover study with long-term follow-up. Neurology. 1975;25(7):603–606. doi: 10.1212/wnl.25.7.603.

20. Parkes J.D., Baxter R.C., Marsden C.D., Rees J.E. Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1974;37(4):422–426. doi: 10.1136/jnnp.37.4.422.

21. Katunina E.A., Avakyan G.N., Titova N.V., Bezdolny Yu.N., Malykhina E.A. Levodopa: from a discovery to new elaborations. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(4):97–103. (In Russ.) Available at: https://mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova/2010/4/031997-72982010418.

22. Deleu D., Northway M.G., Hanssens Y. Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson’s Disease. Clin Pharmacokinet. 2002;41(4):261–309. doi: 10.2165/00003088-200241040-00003.

23. Rajput A.H. Levodopa Prolongs Life Expectancy and Is Non-Toxic to Substantia Nigra. Parkinsonism Relat Disord. 2001;8(2):95–100. doi: 10.1016/s1353-8020(01)00023-2.

24. Levin O.S. Treatment of early-stage Parkinson’s disease. V mire lekarstv: Klinicheskaya farmakologiya i farmakoterapiya = In the World of Drugs: Clinical Pharmacology and Pharmacotherapy. 2001;1:41–47. (In Russ.).

25. Titova N., Levin O., Katunina E., Ray Chaudhuri K. ‘Levodopa Phobia’: A Review of a Not Uncommon and Consequential Phenomenon. NPJ Parkinsons Dis. 2018;4:31. doi: 10.1038/s41531-018-0067-z.

26. Ku S., Glass G.A. Age of Parkinson’s Disease Onset as a Predictor for the Development of Dyskinesia. Mov Disord. 2010;25(9):1177–1182. doi: 10.1002/mds.23068.

27. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A. et al. Levodopa and the Progression of Parkinson’s Disease. N Engl J Med. 2004;351(24):2498–2508. doi: 10.1056/NEJMoa033447.

28. Fahn S., Isgreen W.P. Long-term evaluation of amantadine and levodopa combination in parkinsonism by double-blind crossover analyses. Neurology. 1975;25(8):695–700. doi: 10.1212/wnl.25.8.695.

29. Tomlinson C.L., Stowe R., Patel S., Rick C., Gray R., Clarke C.E. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25(15):2649–2653. doi: 10.1002/mds.23429.

30. Aquino C.C., Fox S.H. Clinical spectrum of levodopa-induced complications. Mov Disord. 2015;30(1):80–89. doi: 10.1002/mds.26125.

31. Stocchi F., Antonini A., Barone P., Tinazzi M., Zappia M., Onofrj M. et al. Early DEtection of wEaring off in Parkinson disease: the DEEP study. Parkinsonism Relat Disord. 2014;20(2):204–211. doi: 10.1016/j.parkreldis.2013.10.027.

32. Chou K.L., Stacy M., Simuni T., Miyasaki J., Oertel W.H., Sethi K. et al. The spectrum of «off» in Parkinson’s disease: What have we learned over 40 years? Parkinsonism Relat Disord. 2018;51:9–16. doi: 10.1016/j.parkreldis.2018.02.001.

33. Stowe R., Ives N., Clarke C.E., Deane K., van Hilten, Wheatley K. et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson’s disease patients with motor complications. Cochrane Database Syst Rev. 2010;(7):CD007166. doi: 10.1002/14651858.CD007166.pub2.

34. Nutt J.G., Woodward W.R., Hammerstad J.P., Carter J.H., Anderson J.L. The «on-off» phenomenon in Parkinson’s disease. Relation to levodopa absorption and transport. N Engl J Med. 1984;310(8):483–488. doi: 10.1056/NEJM198402233100802.

35. Leenders K.L., Poewe W.H., Palmer A.J., Brenton D.P., Frackowiak R.S. Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol. 1986;20(2):258–262. doi: 10.1002/ana.410200212.

36. Baruzzi A., Contin M., Riva R., Procaccianti G., Albani F., Tonello C. et al. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. Clin Neuropharmacol. 1987;10(6):527–537. doi: 10.1097/00002826-198712000-00004.

37. Katunina E.A., Titova N.V. Levodopa-induced dyskinesias in Parkinson’s disease: pathogenesis, clinical features, treatment approaches. Farmateka = Farmateca. 2014;(10–3):58–69. (In Russ.) Available at: https://elibrary.ru/item.asp?id=22374467.

38. Schrag A., Quinn N. Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain. 2000;123(11):2297–2305. doi: 10.1093/brain/123.11.2297.

39. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448–458. doi: 10.1002/mds.1090.

40. Chase T.N., Engber T.M., Mouradian M.M. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson’s disease. Adv Neurol. 1996;69:497–501. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8615171.

41. Blanchet P.J., Konitsiotis S., Chase T.N. Amantadine reduces levodopainduced dyskinesias in parkinsonian monkeys. Mov Disord. 1998;13(5):798–802. doi: 10.1002/mds.870130507.

42. Thomas A., Iacono D., Luciano A.L., Armellino K., Di Iorio A., Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2004;75(1):141–143. Available at: https://ncbi.nlm.nih.gov/pubmed/14707325.

43. Wolf E., Seppi K., Katzenschlager R., Hochschorner G., Ransmayr G., Schwingenschuh P. et al. Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease. Mov Disord. 2010;25(10):1357–1363. doi: 10.1002/mds.23034.

44. Rajput A.H., Rajput A., Lang A.E., Kumar R., Uitti R.J., Galvez-Jimenez N. New use for an old drug: amantadine benefits levodopa-induced dyskinesia. Mov Disord. 1998;13(5):851. doi: 10.1002/mds.870130520.

45. Luginger E., Wenning G.K., Bösch S., Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson’s disease. Mov Disord. 2000;15(5):873–878. doi: 10.1002/1531-8257(200009)15:5<873::aidmds1017>3.0.co;2-i.

46. Snow B.J., Macdonald L., Mcauley D., Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson’s disease: a double-blind, placebo-controlled study. Clin Neuropharmacol. 2000;23(2):82–85. doi: 10.1097/00002826-200003000-00004.

47. Da Silva-Junior F.P., Braga-Neto P., Sueli Monte F., de Bruin V.M. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism Relat Disord. 2005;11(7):449–452. doi: 10.1016/j.parkreldis.2005.05.008.

48. Sawada H., Oeda T., Kuno S., Nomoto M., Yamamoto K., Yamamoto M. et al. Amantadine for dyskinesias in Parkinson’s disease: a randomized controlled trial. PLoS One. 2010;5(12):e15298. doi: 10.1371/journal.pone.0015298.

49. Goetz C.G., Stebbins G.T., Chung K.A., Hauser R.A., Miyasaki J.M., Nicholas A.P. et al. Which dyskinesia scale best detects treatment response? Mov Disord. 2013;28(3):341–346. doi: 10.1002/mds.25321.

50. Verhagen Metman L., Del Dotto P., van den Munckhof P., Fang J., Mouradian M.M., Chase T.N. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology. 1998;50(5):1323–1326. doi: 10.1212/wnl.50.5.1323.

51. Metman L.V., Del Dotto P., LePoole K., Konitsiotis S., Fang J., Chase T.N. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol. 1999;56(11):1383–1386. doi: 10.1001/archneur.56.11.1383.

52. Pahwa R., Tanner C.M., Hauser R.A., Isaacson S.H., Nausieda P.A., Truong D.D. et al. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. JAMA Neurol. 2017;74(8):941–949. doi: 10.1001/jamaneurol.2017.0943.

53. Růzicka E., Streitová H., Jech R., Kanovský P., Roth J., Rektorová I. et al. Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson’s disease. J Neural Transm (Vienna). 2000;107(11):1297–1306. doi: 10.1007/s007020070019.

54. Del Dotto P., Pavese N., Gambaccini G., Bernardini S., Metman L.V., Chase T.N., Bonuccelli U. Intravenous amantadine improves levadopainduced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord. 2001;16(3):515–520. doi: 10.1002/mds.1112.

55. Levin O.S. Acute decompensations in Parkinson’s disease. Effektivnaya farmakoterapiya. Nevrologiya i рsikhiatriya = Effective Pharmacotherapy. Neurology and Psychiatry. 2011;(17):22–29. (In Russ.) Available at: https://elibrary.ru/item.asp?id=21651334.

56. Martinez-Martin P., Catalan M.J., Benito-Leon J., Moreno A.O., Zamarbide I., Cubo E. et al. Impact of fatigue in Parkinson’s disease: the Fatigue Impact Scale for Daily Use (D-FIS). Qual Life Res. 2006;15(4):597–606. doi: 10.1007/s11136-005-4181-0.

57. Ory-Magne F., Corvol J.C., Azulay J.P., Bonnet A.M., Brefel-Courbon C., Damier P. et al. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology. 2014;82(4):300–307. doi: 10.1212/WNL.0000000000000050.

58. Taus C., Giuliani G., Pucci E., D’Amico R., Solari A. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2003;(2):CD002818. doi: 10.1002/14651858.CD002818.

59. Uitti R.J., Rajput A.H., Ahlskog J.E., Offord K.P., Schroeder D.R., Ho M.M. et al. Amantadine treatment is an independent predictor of improved survival in Parkinson’s disease. Neurology. 1996;46(6):1551–1556. doi: 10.1212/wnl.46.6.1551.

60. Inzelberg R., Bonuccelli U., Schechtman E., Miniowich A., Strugatsky R., Ceravolo R. et al. Association between amantadine and the onset of dementia in Parkinson’s disease. Mov Disord. 2006;21(9):1375–1379. doi: 10.1002/mds.20968.